Associations

Associations

Adjuvant Therapy with Atezolizumab and Bevacizumab Show Promising Results for Patients with Hepatocellular Carcinoma

Results from the phase III IMbrave050 clinical trial presented at the AACR Annual Meeting 2023 demonstrate that adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) significantly increases recurrence-free survival in patients with hepatocellular carcinoma (HCC) following surgical resection or ablation. The trial, led by senior consultant surgeon Pierce Chow, FRCS(